Core Viewpoint - The recent performance of alternative medical theme funds in early 2026 has significantly outperformed their 2025 annual returns, primarily driven by funds focusing on AI medical technology rather than traditional innovative drugs [1][2]. Group 1: Fund Performance - As of January 14, 2026, medical theme funds accounted for a substantial portion of the top-performing products, with several funds achieving returns in just two weeks that exceeded their entire 2025 performance [2]. - For instance, the Galaxy Kang Le Mixed Fund achieved a return of 24% in the first two weeks of 2026, compared to a 17.05% return for the entirety of 2025 [2]. - The Wan Jia Health Industry Fund saw a remarkable return of 26.55% in the same period, despite a lackluster performance in 2025 [2]. Group 2: Shift in Investment Focus - Many medical theme funds that underperformed in 2025 have shifted their focus from innovative drugs to AI-driven medical technology, including medical software and internet applications [3]. - The resurgence of interest in AI applications in the medical field has led to a renewed performance in these funds, which had previously lagged behind the market [3]. Group 3: Individual Stock Impact - Individual stock performance has played a crucial role in driving fund performance, with some funds experiencing significant gains from just a few high-performing stocks [4]. - For example, the Wan Jia Health Industry Fund transitioned from a focus on innovative drugs to AI and medical technology stocks, leading to a rapid increase in fund performance [4]. - The Tai Kang Medical Health Fund also benefited from a small-cap stock, Ark Health, which saw its price double in a short period, significantly boosting the fund's ranking [5]. Group 4: Future Outlook for AI Medical Sector - Fund managers anticipate that the AI medical sector will see substantial investment opportunities in the coming years, driven by policy support and technological advancements [6][7]. - The implementation of favorable policies by regulatory bodies is expected to catalyze growth in the AI medical field, with projections for a significant increase in commercial applications [6]. - The ongoing development of computational models and infrastructure is likely to enhance the effectiveness and adoption of AI in healthcare, creating a positive feedback loop for demand [7].

Core Insights - Many fund managers issued "apology letters" in their 2025 semi-annual reports, reflecting underperformance and the challenges faced in a rapidly changing A-share market [2][3] - The apologies highlight individual judgment errors and the broader issues of valuation system reconstruction and investment paradigm shifts [2][3] Group 1: Fund Performance and Apologies - Fund manager Fu Hongzhe of Taikang Medical Health Fund acknowledged underperformance, attributing it to overly conservative operations and missed opportunities in innovative drug assets [3][4] - Xu Jun from Guolianan Fund also apologized for the underperformance of his fund, citing a strategy that failed to adapt to the "stronger get stronger" market dynamics [5][6] - Even funds that achieved positive returns, like Huaxia Fund's Xu Xiaohui, expressed regret for not meeting expectations due to underestimating market valuation fluctuations [5][6] Group 2: Investment Strategy Reflections - Fund managers' apologies have sparked discussions on the need for deeper reflections on investment strategies and market adaptability [6][7] - Key areas of misjudgment included excessive concern over geopolitical risks, premature sector switching, and insensitivity to changes in valuation systems [6][7] - The industry is witnessing a shift towards greater transparency and accountability among fund managers, which may foster trust and promote healthy industry development [7] Group 3: Market Outlook and Challenges - The market is expected to face uncertainties in the second half of the year, including macroeconomic recovery, policy implementation, and international relations [7] - Fund managers will be tested on their ability to navigate complex environments while maintaining strategy stability and flexibility [7]